Every 10-Q that Alkermes Inc. plc (ALKS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALKS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALKS filings page.
Alkermes plc reported strong top-line growth for the quarter ended June 30, 2026, with total revenues of 496,009 thousand, up from 390,657 thousand a year earlier, but net income declined to 501 thousand from 87,098 thousand as expenses and interest rose.
For the first six months of 2026, revenues grew to 888,920 thousand from 697,167 thousand, while results swung to a net loss of 65,979 thousand, compared with net income of 109,562 thousand in 2025, largely reflecting the February 2026 acquisition of Avadel Pharmaceuticals.
The Avadel transaction carried preliminary consideration of 2,306,920 thousand, added 1,794,900 thousand of identifiable intangibles and 511,246 thousand of goodwill, and was financed with new term loans totaling 1,525,000 thousand, driving interest expense of 46,817 thousand and negative operating cash flow of 20,560 thousand year to date.
Alkermes plc reported a quarterly net loss after completing a large acquisition. For the three months ended March 31, 2026, revenue rose to $392.9 million from $306.5 million, driven by higher product sales including LUMRYZ, which contributed $39.5 million after the Avadel Pharmaceuticals acquisition.
The company recorded a net loss of $66.5 million, or $0.40 per share, compared with net income of $22.5 million a year earlier, mainly due to higher R&D, selling, general and administrative costs, amortization of new intangibles, and increased interest expense tied to new debt.
Alkermes closed the Avadel deal for about $2.31 billion in total preliminary consideration, recognizing $513.0 million of goodwill and $1.79 billion of intangible assets. To fund the transaction, it drew $1.525 billion of new term loans, which increased total assets to $4.26 billion and reduced cash and cash equivalents to $351.6 million.
Alkermes plc (ALKS) reported Q3 2025 results with total revenue of $394.2 million, up modestly from $378.1 million a year ago. Product sales rose to $317.4 million, led by VIVITROL $121.1 million, ARISTADA/ARISTADA INITIO $98.1 million, and LYBALVI $98.2 million. Manufacturing and royalty revenue declined to $76.8 million, reflecting the August 2024 expiry of U.S. royalties on INVEGA SUSTENNA.
Operating income was $89.1 million versus $104.8 million, and net income was $82.8 million (diluted EPS $0.49) versus $92.4 million ($0.55). Year-to-date, revenue was $1.09 billion versus $1.13 billion, with net income of $192.3 million versus $220.6 million.
Cash and cash equivalents increased to $616.4 million from $291.1 million at year-end, supported by $350.7 million in operating cash flow for the first nine months. Short-term investments were $494.7 million. The company reduced Medicaid rebate reserves due to lower-than-expected actual rebates, including approximately $25.3 million for VIVITROL and $12.1 million for ARISTADA/ARISTADA INITIO. Shares outstanding were 165.1 million as of October 24, 2025. No repurchases occurred in 2025; $200.0 million remains authorized.
Alkermes (ALKS) Q2-25 10-Q highlights: Net revenue slipped 2% YoY to $390.7 m as a 36% fall in manufacturing & royalty income (-$46.4 m) outweighed a 14% jump in proprietary product sales to $307.2 m. VIVITROL +9% to $121.7 m, ARISTADA franchise +18% to $101.3 m and LYBALVI +18% to $84.3 m.
Earnings & cash: Operating income from continuing ops declined 15% to $93.0 m; diluted EPS fell to $0.52 from $0.55. R&D spending rose 30% to $77.4 m while SG&A was flat. Lower royalties cut gross margin mix but cost-of-goods remained modest at 12.7% of sales. Operating cash flow rose 49% to $249.0 m, lifting cash & equivalents to $521.2 m (vs $291.1 m YE-24); no long-term debt remains, eliminating interest expense.
Balance sheet: Total assets grew to $2.25 bn; equity improved 11% to $1.62 bn. Share count fell 2% YoY to 165.1 m; $200 m of the $400 m buyback authorization is still available.
Key developments: • Royalty stream from long-acting INVEGA products continued to fade after August-24 U.S. expiry. • Medicaid rebate true-ups cut reserves by $30.1 m, aiding cash. • July-25 settlement with Zydus grants first generic VUMERITY entry only immediately prior to patent expiry. • New U.S. patent (12,311,027) extends ARISTADA protection to 2033.
Outlook: Management signals further revenue mix shift toward proprietary brands, higher R&D for pipeline assets (e.g., alixorexton), and materially higher operating cash following recent U.S. tax law changes.